QOL-20. INCLUDING BRAIN METASTASES PATIENTS IN PSYCHOLOGICAL INTERVENTIONS: A PHASE II SINGLE-ARM INVESTIGATION OF MANAGING CANCER AND LIVING MEANINGFULLY

• DOI: 10.1093/neuonc/noad179.0972
• Publication Date: 2023-11-11T23:27:15Z
• Authors: Ashlee Loughan; Autumn Lanoye; Alexandria Davies; Kelcie Willis; Sarah Braun; Chris Kleva; Amber Fox; Giuliana Zarrella; Gary Rodin
• Keywords: Depression

Abstract BACKGROUND Patients with brain cancer demonstrate substantial psychological distress yet are frequently excluded from research. Managing Cancer and Living Meaningfully (CALM), an expressive-supportive psychotherapy designed to address the challenges faced by patients advanced cancer. CALM is proven reduce depression death-related distress; however, metastases (bMETs) have not been formally examined for CALM’s appropriateness or effectiveness. METHODS In this ongoing Phase II trial, 15 adults bMETs heightened (PHQ/DADDS) participate in a six-session intervention complete satisfaction surveys interviews. Data collection includes established feasibility acceptability metrics, interviews, changes patient reported outcomes (pre-to-post CALM). RESULTS Of 21 screened, enrolled study (73% female; 80% White; Mage = 58yrs). All bMET participants completed baseline assessments, 13 trial initiators, 2 screen fails. To date, 8 treatment. Reasons withdrawal include disinterest topics (n 1) lost follow-up 2). Retention 73%, still active No adverse events were determined be study-related. Perceived benefit was high (4.3/5), all they would recommend program others. Reductions severity demonstrated 6 of (MPHQ Reduction 7.6, range 2-11) death anxiety 7 (MDADDS-F1 14.7, 6-23). CONCLUSIONS Preliminary data suggests that both feasible acceptable among adult bMETs. Enrollment retention rates adequate. report recommendation Overall, scores improved, suggesting may promising neuro-oncology as navigate metastatic These findings support advancement next stage, pilot RCT.